[go: up one dir, main page]

PL3645002T3 - Sposoby leczenia niewydolności serca za pomocą aktywatorów sarkomerów serca - Google Patents

Sposoby leczenia niewydolności serca za pomocą aktywatorów sarkomerów serca

Info

Publication number
PL3645002T3
PL3645002T3 PL18745732.0T PL18745732T PL3645002T3 PL 3645002 T3 PL3645002 T3 PL 3645002T3 PL 18745732 T PL18745732 T PL 18745732T PL 3645002 T3 PL3645002 T3 PL 3645002T3
Authority
PL
Poland
Prior art keywords
activators
treatment
methods
heart failure
cardiac sarcomere
Prior art date
Application number
PL18745732.0T
Other languages
English (en)
Inventor
Narimon HONARPOUR
Fady Malik
Original Assignee
Amgen Inc.
Cytokinetics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc., Cytokinetics, Inc. filed Critical Amgen Inc.
Publication of PL3645002T3 publication Critical patent/PL3645002T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL18745732.0T 2017-06-30 2018-06-29 Sposoby leczenia niewydolności serca za pomocą aktywatorów sarkomerów serca PL3645002T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762527983P 2017-06-30 2017-06-30
PCT/US2018/040181 WO2019006235A1 (en) 2017-06-30 2018-06-29 METHODS OF TREATING CARDIAC INSUFFICIENCY WITH CARDIAC SARCOMER ACTIVATORS

Publications (1)

Publication Number Publication Date
PL3645002T3 true PL3645002T3 (pl) 2025-03-24

Family

ID=63013097

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18745732.0T PL3645002T3 (pl) 2017-06-30 2018-06-29 Sposoby leczenia niewydolności serca za pomocą aktywatorów sarkomerów serca

Country Status (22)

Country Link
US (4) US11576910B2 (pl)
EP (2) EP4512470A3 (pl)
JP (3) JP2020526483A (pl)
CN (1) CN110996953A (pl)
AU (2) AU2018290983B2 (pl)
BR (1) BR112019028046A2 (pl)
CA (1) CA3068588A1 (pl)
DK (1) DK3645002T3 (pl)
ES (1) ES3008457T3 (pl)
FI (1) FI3645002T3 (pl)
HR (1) HRP20241729T1 (pl)
HU (1) HUE069805T2 (pl)
LT (1) LT3645002T (pl)
MA (1) MA49508B1 (pl)
MD (1) MD3645002T2 (pl)
MX (2) MX2020000190A (pl)
PL (1) PL3645002T3 (pl)
PT (1) PT3645002T (pl)
RS (1) RS66581B1 (pl)
SI (1) SI3645002T1 (pl)
SM (1) SMT202500067T1 (pl)
WO (1) WO2019006235A1 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA031185B1 (ru) 2013-03-14 2018-11-30 Эмджен Инк. Гетероциклические соединения и способы их применения
PL3645002T3 (pl) * 2017-06-30 2025-03-24 Amgen Inc. Sposoby leczenia niewydolności serca za pomocą aktywatorów sarkomerów serca
SI3645518T1 (sl) 2017-06-30 2021-11-30 Amgen Inc. Sinteza omekamtiv mekarbila
PL3594199T3 (pl) 2018-07-09 2020-11-16 F.I.S.- Fabbrica Italiana Sintetici S.P.A. Krystaliczny 2-fluoro-3-nitrotoluen i sposób jego wytwarzania
US11465969B2 (en) 2018-08-17 2022-10-11 Cytokinetics, Inc. Salts and crystal forms of omecamtiv mecarbil
WO2020236736A1 (en) * 2019-05-19 2020-11-26 MyoKardia, Inc. Treatment of systolic dysfunction and heart failure with reduced ejection fraction with the compound(r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide
US20230090391A1 (en) * 2020-02-10 2023-03-23 Amgen Inc. Omecamtiv mecarbil tablet
WO2021257456A1 (en) * 2020-06-15 2021-12-23 MyoKardia, Inc. Treatment of atrial dysfunction
KR20230107282A (ko) * 2020-11-12 2023-07-14 암젠 인크 오메캄티브 메카빌을 투여하여 심부전을 치료하는 방법
CN116710139A (zh) * 2020-11-12 2023-09-05 安进股份有限公司 通过施用奥美卡替莫卡必尔治疗心力衰竭的方法
BR112023018095A2 (pt) 2021-03-10 2023-12-12 Amgen Inc Processos para sintetizar 2-fluoro-3-nitrotolueno, 1-(bromometil)-2-fluoro-3-nitrobenzeno e para preparar omecamtiv mecarbil ou um sal do mesmo, um hidrato do mesmo ou um hidrato de sal do mesmo
WO2023164452A2 (en) * 2022-02-22 2023-08-31 Yale University Methods of treating, ameliorating, or preventing heart failure, and methods of promoting heart muscle growth
EP4594307A1 (en) 2022-09-26 2025-08-06 Edgewise Therapeutics, Inc. 1,4-dihydroquinazolinone compounds and uses thereof
WO2024081611A1 (en) * 2022-10-11 2024-04-18 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
AU2024248193A1 (en) 2023-03-27 2025-10-09 Edgewise Therapeutics, Inc. Quinolinone amide compounds and uses thereof
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
CA2320193A1 (en) 1998-02-10 1999-08-19 Welfide Corporation Controlled release preparation
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
WO2004033036A2 (en) 2002-10-04 2004-04-22 Microchips, Inc. Medical device for controlled drug delivery and cardiac monitoring and/or stimulation
PL216049B1 (pl) 2004-06-17 2014-02-28 Cytokinetics Inc Pochodne mocznika, kompozycje zawierajace pochodne mocznika oraz zastosowanie pochodnych mocznika do wytwarzania leku do leczenia niewydolnosci serca
US20070161617A1 (en) 2005-12-15 2007-07-12 Morgan Bradley P Certain chemical entities, compositions and methods
MX2008014418A (es) 2006-05-15 2008-11-27 Wisconsin Alumni Res Found Administracion pulmonar de la 1 alfa, 25-dihidroxivitamina d3 y co-administracion de la homona paratiroidea o calcitonina.
FR2902092B1 (fr) 2006-06-07 2008-09-05 Sapelem Soc Par Actions Simpli Appareil de manutention de charge
CN101657190B (zh) 2007-04-19 2013-09-11 东亚制药株式会社 一种适用于对葡萄糖控制肽进行控释的可生物降解的微球组合物及其制剂
EA031185B1 (ru) 2013-03-14 2018-11-30 Эмджен Инк. Гетероциклические соединения и способы их применения
EP2968180B1 (en) * 2013-03-14 2019-04-24 Amgen Inc. Heterocyclic compounds and their uses
EP3250557B1 (en) 2015-01-29 2024-11-20 Signal Pharmaceuticals, LLC Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
MX379899B (es) 2015-06-26 2025-03-11 Cytokinetics Inc Terapia de combinacion de activador de miosina cardiaca e inhibidor de corriente if del nodo sinusal
WO2018144968A1 (en) 2017-02-06 2018-08-09 Acceleron Pharma Inc. Compositions and methods for treating heart failure
SI3645518T1 (sl) 2017-06-30 2021-11-30 Amgen Inc. Sinteza omekamtiv mekarbila
PL3645002T3 (pl) 2017-06-30 2025-03-24 Amgen Inc. Sposoby leczenia niewydolności serca za pomocą aktywatorów sarkomerów serca
PL3594199T3 (pl) 2018-07-09 2020-11-16 F.I.S.- Fabbrica Italiana Sintetici S.P.A. Krystaliczny 2-fluoro-3-nitrotoluen i sposób jego wytwarzania
EP3820851A1 (en) 2018-07-12 2021-05-19 Assia Chemical Industries Ltd Solid state forms of omecamtiv mecarbil & omecamtiv mecarbil dihcl
EP3599243B1 (en) 2018-07-26 2023-04-12 CVIE Therapeutics Limited 17beta-heterocyclyl-digitalis like compounds for the treatment of heart failure
US11465969B2 (en) 2018-08-17 2022-10-11 Cytokinetics, Inc. Salts and crystal forms of omecamtiv mecarbil
WO2020131574A1 (en) 2018-12-18 2020-06-25 Amgen Inc. Method of reducing aromatic nitro compounds
JP7560134B2 (ja) 2019-03-05 2024-10-02 ウインドトゥリー・セラピューティクス・インコーポレイテッド 急性心不全（ａｈｆ）の治療のためのイスタロキシム含有静脈用製剤
WO2021053189A1 (en) 2019-09-19 2021-03-25 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
WO2021053175A1 (en) 2019-09-19 2021-03-25 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
WO2021070124A1 (en) 2019-10-09 2021-04-15 Dr. Reddy’S Laboratories Limited Alternate processes for the preparation of omecamtiv mecarbil
WO2021070123A1 (en) 2019-10-09 2021-04-15 Dr. Reddy’S Laboratories Limited Solid forms of omecamtiv mecarbil dihydrochloride and processes thereof
BR112022008641A2 (pt) 2019-11-10 2022-09-13 Myokardia Inc Métodos de tratamento com modulador de miosina
GB201918853D0 (en) 2019-12-19 2020-02-05 Lund Lars H Methods of treatment
CN114929671B (zh) 2020-01-03 2024-04-16 苏州科睿思制药有限公司 化合物i二盐酸盐的共晶及其制备方法和用途
US20230090391A1 (en) 2020-02-10 2023-03-23 Amgen Inc. Omecamtiv mecarbil tablet
KR20230107282A (ko) 2020-11-12 2023-07-14 암젠 인크 오메캄티브 메카빌을 투여하여 심부전을 치료하는 방법
BR112023018095A2 (pt) 2021-03-10 2023-12-12 Amgen Inc Processos para sintetizar 2-fluoro-3-nitrotolueno, 1-(bromometil)-2-fluoro-3-nitrobenzeno e para preparar omecamtiv mecarbil ou um sal do mesmo, um hidrato do mesmo ou um hidrato de sal do mesmo
WO2023205291A2 (en) 2022-04-21 2023-10-26 The Board Of Regents Of The University Of Oklahoma Targeting myocardial tissue for delivery of therapeutic and imaging agents
WO2024081611A1 (en) 2022-10-11 2024-04-18 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
US11986474B1 (en) * 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Also Published As

Publication number Publication date
US11576910B2 (en) 2023-02-14
US20230355615A1 (en) 2023-11-09
US20250255862A1 (en) 2025-08-14
AU2018290983B2 (en) 2023-11-23
RS66581B1 (sr) 2025-04-30
MX2022015115A (es) 2023-01-18
DK3645002T3 (da) 2024-12-16
HUE069805T2 (hu) 2025-04-28
PT3645002T (pt) 2025-01-24
MX2020000190A (es) 2020-07-22
WO2019006235A1 (en) 2019-01-03
US20230149394A1 (en) 2023-05-18
AU2024200991A1 (en) 2024-03-07
MA49508A (fr) 2020-05-06
AU2018290983A1 (en) 2020-01-23
BR112019028046A2 (pt) 2020-07-07
MA49508B1 (fr) 2024-12-31
FI3645002T3 (fi) 2025-01-29
SMT202500067T1 (it) 2025-03-12
EP3645002A1 (en) 2020-05-06
MD3645002T2 (ro) 2025-04-30
CN110996953A (zh) 2020-04-10
JP2023088944A (ja) 2023-06-27
US11931358B2 (en) 2024-03-19
EP4512470A2 (en) 2025-02-26
SI3645002T1 (sl) 2025-03-31
EP3645002B1 (en) 2024-10-30
LT3645002T (lt) 2025-02-10
JP2020526483A (ja) 2020-08-31
CA3068588A1 (en) 2019-01-03
ES3008457T3 (en) 2025-03-24
US12295952B2 (en) 2025-05-13
JP2025165979A (ja) 2025-11-05
EP4512470A3 (en) 2025-04-23
AU2024200991B2 (en) 2025-04-10
US20200155547A1 (en) 2020-05-21
HRP20241729T1 (hr) 2025-03-14

Similar Documents

Publication Publication Date Title
PL3645002T3 (pl) Sposoby leczenia niewydolności serca za pomocą aktywatorów sarkomerów serca
EP4230133C0 (en) CONTROLLED AND PRECISE TREATMENT OF CARDIAC TISSUES
IL272300A (en) Mavacamten for use in the treatment of hypertrophic cardiomyopathy
EP3614943A4 (en) IMPROVED ELECTROPORATION OF HEART TISSUE
IL253954A0 (en) Implantable devices and related methods for heart failure monitoring
IL253351A0 (en) Cardiac stimulation of conduction pathways between the atria and ventricles and of tissues associated with these pathways
EP3875139C0 (en) TREATMENT OF VENOUS DISEASES
PL3265053T3 (pl) Sposoby leczenia skóry
PL3402888T3 (pl) Środki i sposoby leczenia hbv
IL247088B (en) Matching and tracking time sequences of heart activation
EP3724219A4 (en) TREATMENT OF FIBROSIS BY GENETICALLY MODIFIED MACROPHAGES
HUE057484T2 (hu) IncRNS-ek szívhipertrófia terápiájára és diagnosztizálására
EP3266380C0 (en) DETERMINATION OF TISSUE THICKNESS
EP3424557A4 (en) INTRAKARDIAL DEFIBRILLATION CATHETER
EP3609500A4 (en) ADIPOCYTE TREATMENT
EP3576790A4 (en) TREATMENT OF DIURETIC RESISTANCE
EP3478822C0 (en) Preservation of microorganisms
EP3436569A4 (en) ADVANCED DIRECT CARDIAL PROGRAMMING
EP3681505C0 (en) IMPROVED TREATMENT OF ATOPIC DERMATITIS USING TRADIPITANT
IL270900A (en) Treatment of cutaneous disorders
EP3066077A4 (en) Treatment of cardiac remodeling and other heart conditions
ES2894844T8 (es) Tratamiento de la calcificación vascular
EP3210575C0 (en) CARDIAC IMPLANT
EP3223903C0 (en) CARDIAC PACING DETECTION AND REGULATION
EP3703820A4 (en) USE OF MIR101 OR MIR128 IN THE TREATMENT OF EPILEPTIC DISORDERS